Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
The study was designed to evaluate the efficacy, safety, and pharmacokinetics of SHR2102 in
patients with advanced solid tumors. The objective of this study was to determine the
dose-limiting toxicity, maximum tolerance and recommended dose of SHR-A2102 in phase II
study.